

Isolated Extracranial Intraosseous Metastasis of an Intracranial Meningioma following Bevacizumab Therapy: Case Report and Review of the Literature

Abstract

Meningiomas account for a significant proportion of all primary intracranial tumors; distant metastasis is quite rare. We report a patient with resected, atypical meningioma. The patient's clinical course over 5 years included two craniotomies, a course of radiation, and a shortened course of bevacizumab. Only 5 months after starting bevacizumab, the patient developed an isolated left clavicular pathological fracture attributable to metastatic anaplastic meningioma. This constitutes the first report of meningioma with isolated extracranial intraosseous metastasis in the modern English literature and highlights concerns associated with the use of anti-angiogenic agents in promoting more invasive tumor phenotypes upon disease recurrence.

Keywords: *Anaplastic meningioma, atypical meningioma, bevacizumab, extracranial intraosseous metastasis*

Introduction

Arising from meningotheial cells of the arachnoid membrane, meningiomas are generally benign tumors, accounting for approximately 15% of all primary central nervous system tumors.^[1-7] Historically, meningiomas have been known to invade local venous sinuses, bone, or soft tissues of the scalp with an incidence of up to 32% in some series.^[8,9] Distal metastases of meningiomas are much more rare, with the most common sites of such metastasis including the lungs, abdominal wall, liver, cervical lymph nodes, long bones, and vertebrae.^[10-26] To date, only one reported case of meningioma metastatic to the clavicle has been reported in the literature, with that case predating modern adjuvant advances, such as the use of stereotactic radiosurgery and bevacizumab therapy, and presenting in a patient with widely disseminated disease.^[27] We report a modern case of an 81-year-old man with progressive, recurrent meningioma with isolated metastasis to the left clavicle.

Case Report

An 81-year-old, right-handed, retired gardener with a distant history of prostatectomy for cancer presented with a

3-week history of right frontal headaches and left arm numbness without weakness. On the day prior to admission, the patient had a complex, partial motor seizure of the left face which progressed to left arm tonic then clonic activity treated by lorazepam and phenytoin. The patient had no secondary generalization but had a postictal period of confusion and sleepiness. Following this episode, the patient returned to his neurological baseline, including numbness of the left arm. Brain magnetic resonance imaging (MRI) demonstrated an approximately 3 cm, extra-axial mass along the right frontal convexity with some underlying edema and mild diffuse atrophy [Figure 1].

The patient underwent a right frontal craniotomy for tumor resection using frameless stereotaxy with formalin-fixed pathology demonstrating a 2.5 cm × 2.4 cm × 2.1 cm soft, tan-white, dural-based tumor with brisk mitoses focally (approximately 9–11/high powered field), rare small foci of necrosis, and hypercellularity, all consistent with a World Health Organization (WHO) Grade II or atypical meningioma [Figure 2]. There was a discussion with the patient and family over upfront focal radiation versus following closely with MRIs, and radiation was deferred.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Mukherjee D, Hu JL, Chu RM. Isolated extracranial intraosseous metastasis of an intracranial meningioma following bevacizumab therapy: Case report and review of the literature. *Asian J Neurosurg* 2018;13:98-101.

**Debraj Mukherjee,
Jethro L. Hu,
Ray M. Chu**

*Department of Neurosurgery,
Cedars-Sinai Medical Center,
Los Angeles, CA 90048, USA*

Address for correspondence:

*Dr. Debraj Mukherjee,
Department of Neurosurgery,
Cedars-Sinai Medical Center,
8631 W. 3rd Street, Suite 800E,
Los Angeles, CA 90048, USA.
E-mail: debraj.mukherjee@
cshs.org*

Access this article online

Website: www.asianjns.org

DOI: 10.4103/1793-5482.185057

Quick Response Code:






Figure 1: Initial brain magnetic resonance imaging demonstrating a 3 cm, extra-axial mass along the right frontal convexity with some underlying edema and mild diffuse atrophy

From the immediate postoperative period through approximately 2 years postoperatively, the patient continued to have some left-handed numbness as well as some mild difficulty with memory and word-finding difficulties but was otherwise asymptomatic and independent with a Karnofsky performance score of 90. Routine postoperative MRI imaging 2 years after resection demonstrated a new right frontal dural-based enhancing mass measuring <1 cm in diameter and associated with some modest new surrounding edema as well as residual postoperative changes.

Given the patient's advanced age and the relatively small size of the recurrent lesion, the patient underwent gamma knife radiosurgery with a treatment consisting of two 14 mm collimator isocenters with 18 gray to the 75% isodose line using trunnions. This procedure was tolerated without complication and repeat MRI imaging approximately 6 months following the procedure demonstrated a smaller right frontal lesion.

Although his symptoms remained stable, routine MRI imaging every 6 months eventually demonstrated the further growth of the right frontal parasagittal lesion 2 years following the patient's initial gamma knife radiosurgery. Thus, the patient underwent a second round of gamma knife radiosurgery consisting of two 14 mm collimator isocenters and two 8 mm collimator isocenters with 13 gray to the 50% isodose line. There was a portion of the tumor that had an unusual shape inferiorly, however, and thus hypofractionated stereotactic radiosurgery using a 7-field IMRT approach was used to treat this area of the tumor.

Over the subsequent year, the patient's clinical course was complicated by a deep vein thrombosis and focal seizures involving the left arm, for which he was started on levetiracetam. Approximately, 1½ years after his preceding last dose of radiosurgery, the patient developed slurred speech




Figure 2: Formalin-fixed pathological specimen with brisk mitoses, small foci of necrosis rarely, and hypercellularity, all consistent with a World Health Organization Grade II or atypical meningioma

and a significantly unsteady gait due to worsening left sided weakness. Subsequent MRI demonstrated a large right-sided extra-axial mass with extension through the patient's craniotomy defect, consistent with a recurrent meningioma. Thus, the patient was taken to the operating room for right-sided craniotomy for recurrent tumor resection. Of note, some elements of the tumor were invading the skull. Pathology demonstrated an extensively necrotizing WHO Grade III malignant meningioma with a sarcomatoid growth pattern and up to 80 mitotic figures per square millimeter, nuclear sheeting, and nucleolar prominence. Following surgical resection, the patient additionally underwent broader field 25 gray radiotherapy delivered in five fractions and was started on bevacizumab therapy.

Approximately 5 months later, the patient began to develop persistent left clavicular pain after a mechanical fall. Plain X-ray imaging of the clavicle was notable for a mass lesion and adjacent pathological fracture [Figure 3]. The patient underwent an incisional biopsy of the left clavicle with internal fixation and bone grafting to correct the pathological fracture. Pathology demonstrated an unencapsulated neoplasm with nests of epithelioid and spindle cells along with prominent nucleoli, entrapping, and infiltrating skeletal muscle and bone trabeculae, consistent with a metastatic anaplastic meningioma.

Following this orthopedic procedure, the patient's clavicular pain abated. His bevacizumab therapy was halted as he had developed tumor progression while on chemotherapy, coupled with his significant preceding history of deep vein thrombosis. Radiation to the clavicle was discussed with the family, but given the patient's deteriorating condition, his family opted for hospice care.

Discussion

Meningiomas are a relatively common intracranial tumor, accounting for up to 20% of all primary neoplasms.^[28]



Figure 3: Plain X-ray of the left clavicle demonstrating a mass lesion and adjacent pathological fracture

Although generally benign, recurrence is not uncommon for atypical or anaplastic variants, with 5 years recurrence rates of 38% and 78% for atypical and anaplastic variants, respectively.^[29] Even among higher grade meningiomas with recurrence, metastasis is rare, reaching approximately 5% for atypical meningiomas and 30% for anaplastic or malignant meningiomas.^[30]

Several histological parameters are predictive of rapid recurrence, including high cellularity, mitotic rate, nuclear pleomorphism, and invasion of adjacent structures.^[31-33] According to one case series, such features also seem to predict distant metastatic spread.^[34] Many such features were present in the current case, particularly after transformation into an anaplastic meningioma.

Unique in this case report, however, is the location of the distant metastasis. While meningiomas are thought to metastasize distantly via the spread of cerebrospinal fluid or the venous system predominantly to the lungs, pleura, and liver, this case is only the second reported in the literature to metastasize to the relatively avascular clavicle, far from any source of potential cerebrospinal fluid spread. The only prior report of distant metastasis of a meningioma to the clavicle was reported in a patient with markedly diffuse distant disease. Though it is unclear the particular mechanism by which this meningioma may have spread to the clavicle, it is important to note that currently postulated mechanisms of spread, namely via cerebrospinal fluid or the venous system, may have played a role. Neuro-oncologists and neurosurgeons should remain aware of the possibility of distant, often isolated spread of atypical or anaplastic meningiomas. For patients with meningiomas, especially aggressive meningiomas, metastasis to the bone is a possible though rare entity. Providers should have an index of suspicion for such patients presenting with referred skeletal pain.

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is Food and Drug

Administration-approved for the treatment of a variety of malignancies, including recurrent glioblastoma. There are also several case reports that suggest activity against recurrent or progressive meningiomas.^[35-37] One of the theoretical concerns of treatment with an anti-angiogenic agent such as bevacizumab is the potential for promoting a more invasive tumor phenotype. Several reports contend that glioblastoma patients treated with bevacizumab are more likely to present with infiltrative or multifocal disease at recurrence.^[38-40] It is reasonable to hypothesize that the risk of promoting tumor invasion may apply to other aggressive types of brain tumors, such as anaplastic meningioma. Ultimately, in this case, it is not completely clear whether concurrent bevacizumab therapy contributed to distant metastasis, but the possibility cannot be excluded.

Conclusion

This case report constitutes the first report of a meningioma with isolated osseous metastasis to the clavicle in the English literature. Clinicians should be aware of the potential for atypical or anaplastic meningiomas to metastasize extracranially, particularly when using anti-angiogenic agents such as bevacizumab.

Acknowledgments

The authors would like to acknowledge Serguei I. Bannykh, M.D., Ph.D. and Amin J. Mirhadi, M.D. for their work in caring for this patient.

Financial support and sponsorship

This study was funded in part with support from the Robert Wood Johnson Foundation, American Medical Association Foundation, and National Institutes of Health.

Conflicts of interest

There are no conflicts of interest.

References

1. Kleihues P, Burguer PC, Scheithauer BW, Zulch KJ. Histological typing of tumours of the central nervous system. WHO 1993;2:37-42.
2. Enam SA, Abdulrauf S, Mehta B, Malik GM, Mahmood A. Metastasis in meningioma. *Acta Neurochir (Wien)* 1996;138:1172-7.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, *et al.* The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 2007;114:97-109.
4. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. *Neurosurgery* 2005;57:1088-95.
5. Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT Jr, Omalu B. Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. *Neurosurgery* 2004;55:1163-73.
6. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD. Epidemiology of intracranial meningioma. *Cancer* 1993;72:639-48.
7. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. *Lancet* 2004;363:1535-43.

8. Teague SD, Conces DJ Jr. Metastatic meningioma to the lungs. *J Thorac Imaging* 2005;20:58-60.
9. Lüdemann WO, Obler R, Tatagiba M, Samii M. Seeding of malignant meningioma along a surgical trajectory on the scalp. Case report and review of the literature. *J Neurosurg* 2002;97:683-6.
10. Kepes JJ. Meningiomas: Biology, pathology and differential diagnosis. *Masson Monographs* 1982;4:190-200.
11. Abboud M, Haddad G, Kattar M, Aburiziq I, Geara FB. Extraneural metastases from cranial meningioma: A case report. *Radiat Oncol* 2009;4:20.
12. Asghar AH, Mahmood H, Faheem M, Rizvi S, Irfan J. Hepatic and skeletal metastases from primary intracranial atypical meningioma. *J Coll Physicians Surg Pak* 2009;19:316-7.
13. Batson OV. The function of the vertebral veins and their role in the spread of metastases 1940. *Clin Orthop Relat Res* 1995;312:4-9.
14. Chamberlain MC, Glantz MJ. Cerebrospinal fluid-disseminated meningioma. *Cancer* 2005;103:1427-30.
15. Cramer P, Thomale UW, Okuducu AF, Lemke AJ, Stockhammer F, Woiciehowsky C. An atypical spinal meningioma with CSF metastasis: Fatal progression despite aggressive treatment. Case report. *J Neurosurg Spine* 2005;3:153-8.
16. Erkutlu I, Buyukhatipoglu H, Alptekin M, Berkyurek E, Tutar E, Gok A. Spinal drop metastases from a papillary meningioma: A case report and review of the literature: Utility of CSF sampling. *Med Oncol* 2009;26:242-6.
17. Estanislau ES, Carvalho GT, Reis BL, de Freitas Barbosa W, Brandão RA, Sousa AA, *et al.* Malignant meningioma with extracranial metastases. *Arq Neuropsiquiatr* 2009;67:730-2.
18. Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. *Br J Radiol* 1999;72:513-6.
19. Frank BL, Harrop JS, Hanna A, Ratliff J. Cervical extradural meningioma: Case report and literature review. *J Spinal Cord Med* 2008;31:302-5.
20. Karasick JL, Mullan SF. A survey of metastatic meningiomas. *J Neurosurg* 1974;40:206-12.
21. LeMay DR, Bucci MN, Farhat SM. Malignant transformation of recurrent meningioma with pulmonary metastases. *Surg Neurol* 1989;31:365-8.
22. Miller DC, Ojemann RG, Proppe KH, McGinnis BD, Grillo HC. Benign metastasizing meningioma. Case report. *J Neurosurg* 1985;62:763-6.
23. Shuangshoti S, Hongsaprabhas C, Netsky MG. Metastasizing meningioma. *Cancer* 1970;26:832-41.
24. Slavin ML. Metastatic malignant meningioma. *J Clin Neuroophthalmol* 1989;9:55-9.
25. Strange RR, Tovi D, Nordenstam H. Meningioma with intracerebral, cerebellar and visceral metastases. *J Neurosurg* 1964;21:1098-102.
26. Sujit Kumar GS, Chacko G, Chacko AG, Haran RP. Multiple extracranial metastases from intradiploic meningioma. *Neurol India* 2009;57:96-7.
27. Meredith JM, Butler LF. Malignant meningioma: Case report of a parasagittal meningioma of the right cerebral hemisphere with multiple extracranial metastases to the vertebra, sacrum, ribs, clavicle, lungs, liver, left kidney, mediastinum, and pancreas. *S Med J* 1958;52:1035-40.
28. Wara WM, Sheline GE, Newman H, Townsend JJ, Boldrey EB. Radiation therapy of meningiomas. *Am J Roentgenol Radium Ther Nucl Med* 1975;123:453-8.
29. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcome. *Surg Neurol* 1986;25:233-42.
30. Erman T, Hanta I, Hacıyakupoglu S, Zorludemir S, Zeren H, Göçer AI. Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: A case report and review of the literature. *J Neurooncol* 2005;74:179-81.
31. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 1957;20:22-39.
32. Skullerud K, Löken AC. The prognosis in meningiomas. *Acta Neuropathol* 1974;29:337-44.
33. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. *Am J Surg Pathol* 1986;10:836-43.
34. New PF, Hesselink JR, O'Carroll CP, Kleinman GM. Malignant meningiomas: CT and histologic criteria, including a new CT sign. *AJNR Am J Neuroradiol* 1982;3:267-76.
35. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. *Ann Oncol* 2010;21:2445-6.
36. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. *Ann Oncol* 2011;22:990-1.
37. Wilson TJ, Heth JA. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer. *J Clin Neurosci* 2012;19:468-9.
38. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, *et al.* Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. *Neurology* 2008;70:779-87.
39. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, *et al.* Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. *Neurology* 2009;73:1200-6.
40. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, *et al.* Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. *J Neurooncol* 2009;91:329-36.